EA202091279A1 - Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения - Google Patents
Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их полученияInfo
- Publication number
- EA202091279A1 EA202091279A1 EA202091279A EA202091279A EA202091279A1 EA 202091279 A1 EA202091279 A1 EA 202091279A1 EA 202091279 A EA202091279 A EA 202091279A EA 202091279 A EA202091279 A EA 202091279A EA 202091279 A1 EA202091279 A1 EA 202091279A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- preparation
- methods
- polymorphes
- pyrimidinylamino
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретение относится к кристаллическим полиморфным и аморфной формам 2-метил-2-(3-метил-4-(4-(метиламин)-5-(трифторметил)пиримидин-2-иламино)-1H-пиразол-1-ил)пропаннитрила или его сольватов, таутомеров и фармацевтически приемлемых солей или к их сокристаллам и способам их получения.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589276P | 2017-11-21 | 2017-11-21 | |
| PCT/US2018/062102 WO2019104086A1 (en) | 2017-11-21 | 2018-11-20 | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091279A1 true EA202091279A1 (ru) | 2020-08-19 |
Family
ID=66631734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091279A EA202091279A1 (ru) | 2017-11-21 | 2018-11-20 | Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10370361B2 (ru) |
| EP (1) | EP3717473B1 (ru) |
| JP (1) | JP7303821B2 (ru) |
| KR (1) | KR20200089713A (ru) |
| CN (1) | CN111819174A (ru) |
| AR (1) | AR113893A1 (ru) |
| AU (1) | AU2018372180B2 (ru) |
| BR (1) | BR112020010215A2 (ru) |
| CA (1) | CA3083022A1 (ru) |
| CL (1) | CL2020001346A1 (ru) |
| CO (1) | CO2020006206A2 (ru) |
| CR (1) | CR20200216A (ru) |
| EA (1) | EA202091279A1 (ru) |
| ES (1) | ES2975319T3 (ru) |
| IL (1) | IL274824A (ru) |
| JO (1) | JOP20200128A1 (ru) |
| MA (1) | MA51222A (ru) |
| MX (1) | MX2020005332A (ru) |
| PE (1) | PE20210157A1 (ru) |
| SG (1) | SG11202004733WA (ru) |
| TW (1) | TWI823878B (ru) |
| UA (1) | UA126414C2 (ru) |
| WO (1) | WO2019104086A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR113893A1 (es) | 2017-11-21 | 2020-06-24 | Denali Therapeutics Inc | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción |
| AU2018392599A1 (en) | 2017-12-20 | 2020-07-09 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| CN103038230B (zh) | 2010-06-04 | 2016-05-25 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| LT3124483T (lt) * | 2010-11-10 | 2019-09-25 | Genentech, Inc. | Pirazolo aminopirimidino dariniai, kaip lrrk2 moduliatoriai |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| BR112014011219B1 (pt) | 2011-11-29 | 2022-08-23 | Genentech, Inc. | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| BR112014011850B1 (pt) | 2011-11-29 | 2022-01-11 | Genentech, Inc | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| US8791130B2 (en) | 2011-11-29 | 2014-07-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
| KR102091894B1 (ko) | 2012-05-03 | 2020-03-20 | 제넨테크, 인크. | Lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
| BR112014027117B1 (pt) | 2012-05-03 | 2022-09-06 | Genentech, Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição |
| PE20240221A1 (es) | 2016-06-16 | 2024-02-16 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos |
| AR113893A1 (es) * | 2017-11-21 | 2020-06-24 | Denali Therapeutics Inc | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción |
-
2018
- 2018-11-20 AR ARP180103389A patent/AR113893A1/es unknown
- 2018-11-20 US US16/197,037 patent/US10370361B2/en active Active
- 2018-11-20 KR KR1020207017598A patent/KR20200089713A/ko not_active Application Discontinuation
- 2018-11-20 SG SG11202004733WA patent/SG11202004733WA/en unknown
- 2018-11-20 MX MX2020005332A patent/MX2020005332A/es unknown
- 2018-11-20 EA EA202091279A patent/EA202091279A1/ru unknown
- 2018-11-20 JO JOP/2020/0128A patent/JOP20200128A1/ar unknown
- 2018-11-20 ES ES18881859T patent/ES2975319T3/es active Active
- 2018-11-20 AU AU2018372180A patent/AU2018372180B2/en active Active
- 2018-11-20 UA UAA202003681A patent/UA126414C2/uk unknown
- 2018-11-20 PE PE2020000558A patent/PE20210157A1/es unknown
- 2018-11-20 EP EP18881859.5A patent/EP3717473B1/en active Active
- 2018-11-20 WO PCT/US2018/062102 patent/WO2019104086A1/en active Application Filing
- 2018-11-20 TW TW107141257A patent/TWI823878B/zh active
- 2018-11-20 MA MA051222A patent/MA51222A/fr unknown
- 2018-11-20 CN CN201880081321.5A patent/CN111819174A/zh active Pending
- 2018-11-20 CR CR20200216A patent/CR20200216A/es unknown
- 2018-11-20 BR BR112020010215-6A patent/BR112020010215A2/pt unknown
- 2018-11-20 JP JP2020545076A patent/JP7303821B2/ja active Active
- 2018-11-20 CA CA3083022A patent/CA3083022A1/en active Pending
-
2019
- 2019-06-20 US US16/447,713 patent/US10851088B2/en active Active
-
2020
- 2020-05-20 IL IL274824A patent/IL274824A/en unknown
- 2020-05-21 CL CL2020001346A patent/CL2020001346A1/es unknown
- 2020-05-21 CO CONC2020/0006206A patent/CO2020006206A2/es unknown
- 2020-11-27 US US17/105,870 patent/US11427571B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CR20200216A (es) | 2021-03-19 |
| EP3717473B1 (en) | 2024-01-10 |
| US11427571B2 (en) | 2022-08-30 |
| TWI823878B (zh) | 2023-12-01 |
| EP3717473A4 (en) | 2021-07-07 |
| CL2020001346A1 (es) | 2020-11-20 |
| JOP20200128A1 (ar) | 2020-05-21 |
| JP2021504450A (ja) | 2021-02-15 |
| EP3717473A1 (en) | 2020-10-07 |
| US10851088B2 (en) | 2020-12-01 |
| UA126414C2 (uk) | 2022-09-28 |
| CA3083022A1 (en) | 2019-05-31 |
| US20190194170A1 (en) | 2019-06-27 |
| TW201925190A (zh) | 2019-07-01 |
| AU2018372180A1 (en) | 2020-06-18 |
| MX2020005332A (es) | 2021-01-08 |
| US20190315723A1 (en) | 2019-10-17 |
| KR20200089713A (ko) | 2020-07-27 |
| AR113893A1 (es) | 2020-06-24 |
| CO2020006206A2 (es) | 2020-08-10 |
| PE20210157A1 (es) | 2021-01-26 |
| US20210087176A1 (en) | 2021-03-25 |
| US10370361B2 (en) | 2019-08-06 |
| ES2975319T3 (es) | 2024-07-04 |
| SG11202004733WA (en) | 2020-06-29 |
| BR112020010215A2 (pt) | 2020-11-03 |
| AU2018372180B2 (en) | 2023-08-17 |
| WO2019104086A1 (en) | 2019-05-31 |
| MA51222A (fr) | 2020-10-07 |
| IL274824A (en) | 2020-07-30 |
| CN111819174A (zh) | 2020-10-23 |
| JP7303821B2 (ja) | 2023-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| EA201890001A1 (ru) | Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk) | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| IL274488B1 (en) | Crystal forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| EA202192029A1 (ru) | Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| EA201790892A1 (ru) | Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA202091279A1 (ru) | Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| EA201692356A1 (ru) | Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида | |
| EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst | |
| EA202191833A1 (ru) | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
| EA202192320A1 (ru) | Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-[2-(трифторметил)пиридин-4-ил]-1h-пиразол-4-карбоксамида | |
| EA201890525A1 (ru) | Кристаллическая форма 2-(2,6-дихлорфенил)-1-[(1s,3r)-3-(гидроксиметил)-5-(3-гидрокси-3-метилбутил)-1-метил-3,4-дигидроизохинолин-2(1h)-ил]этанона для лечения болезни паркинсона | |
| PH12020551465A1 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
| DK3658547T3 (da) | Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid | |
| WO2015111085A3 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
| EA201792558A1 (ru) | Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль | |
| SG11202005983TA (en) | Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors | |
| EA202193285A1 (ru) | Состав с модифицированным высвобождением соединения пиримидиниламинопиразола и способы лечения | |
| EA201600507A2 (ru) | Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr | |
| MA53914A (fr) | Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton |